Journal
INTERNATIONAL IMMUNOPHARMACOLOGY
Volume 9, Issue 3, Pages 340-346Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.intimp.2008.12.012
Keywords
CD4(+) T cells; CD25; Cysteine protease; Natural product; Bromelain
Categories
Funding
- NIH/AI [R01 HL-43573, NIH/NCCAM FG32-AT001569, NIH/NCCAM K08]
- Competitive Technologies Inc.
- NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE [K08AT004252] Funding Source: NIH RePORTER
- NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [F32AT001569] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043573] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Bromelain (Br), an extract from pineapple stem with cysteine protease activity, exerts anti-inflammatory effects in a number of inflammatory models. We have previously shown that Br treatment decreased activated CD4(+) T cells and has a therapeutic role in an ovalbumin-induced murine model of allergic airway disease. The current study was designed to determine the effect of Br on CD4(+) T cell activation, specifically the expression of CD25 in vitro. CD25 is up regulated upon T cell activation, found as a soluble fraction (sCD25) and is a therapeutic target in inflammation, autoimmunity and allergy. Br treatment of anti-CD3 stimulated CD4(+) T cells reduced CD25 expression in a dose and time dependent manner. This reduction of CD25 was dependent on the proteolytic action of Br as the addition of E64 (a cysteine protease inhibitor) abrogated this response. The concentration of sCD25 was increased in supernatants of Br treated activated CD4(+) T cells as compared to control cells, suggesting that Br proteolytically cleaved cell-surface CD25. This novel mechanism of action identifies how Br may exert its therapeutic benefits in inflammatory conditions. (C) 2008 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available